\
&
Contact us
\
&
Contact us
This was 1 year ago
Locationvirtual
ProgrammesThis webinar hosted by the European IP Helpdesk is for early career researchers to outline the basics of Intellectual Property (IP) and of Open Science (OS). The aim is to create awareness of, and to build confidence in, applying the laws of IP to the culture of Open Science, and vice versa. The webinar will show that there is no conflict between IP and Open Science, but on the other hand, “open” does not mean “no IP issues”, nor “free for commercial use”. We will explore the concept of “openness” in its various forms and show how the IP system fits with the essence of OS. We will show examples of how the sharing of IP, data, and publications, can be as open as possible, but closed when necessary.
The registration form is available in the announcement of the webinar on the European IP Helpdesk website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
